A Phase I Study of JNJ-54761414 (Daratumumab) in Japanese Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2017
Price : $35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 16 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 20 May 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov record.